Christian Marth, MD, PhD

Christian Marth, MD, PhD, discusses next steps with pembrolizumab and lenvatinib for use in the advanced or recurrent endometrial cancer treatment paradigm.

Christian Marth, MD, PhD, discusses efficacy and safety findings from the phase 3 LEAP-001 trial in advanced/recurrent endometrial cancer.

Christian Marth, MD, PhD, discusses the unmet needs that led to the phase 3 LEAP-001 trial in advanced/recurrent endometrial cancer and other research efforts of interest.

Christian Marth, MD, PhD, discusses the differences between mismatch repair–deficient and –proficient subtypes of advanced/recurrent endometrial cancer and other research efforts of interest.

Christian Marth, MD, PhD, highlights the prognosis and survival outcomes for patients who are diagnosed with advanced or recurrent endometrial cancer.

Christian Marth, MD, PhD, discusses the LEAP-001 trial of lenvatinib plus pembrolizumab vs chemotherapy in advanced or recurrent endometrial cancer.

Christian Marth, MD, PhD, reviews the adverse effects of pembrolizumab and lenvatinib in the treatment of endometrial cancer, as well as the patient experience with these treatments.

Bradley J. Monk, MD, FACS, FACOG, and Christian Marth, MD, PhD, share treatment approaches to patients with endometrial cancer with a low response rate to chemotherapy, highlighting a biomarker-based approach.

Experts discuss the possibility to avoid use of chemotherapy by using immunotherapy.

Christian Marth, MD, PhD, and Bradley J. Monk, MD, FACS, FACOG, discuss data from the NRG GY018 and RUBY trials regarding the use of immunotherapies for the treatment of endometrial cancer.

Bradley J. Monk, MD, FACS, FACOG, reviews the available chemotherapy options for treating advanced and recurrent endometrial cancer, as well as compares notes with Christian Marth, MD, PhD, on his clinical experience.

Christian Marth, MD, PhD, discusses the prevalence of endometrial cancer, as well as the steps that lead to diagnosis.